Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 2,564 |
|
|||||
| News | - | ||||||
| Day High | 2.85 | Low High |
|||||
| Day Low | 2.75 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| AYTU BioPharma Inc | AYTU | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.0598 | -2.13% | 2.75 | 11:38:55 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.80 | 2.75 | 2.85 | 2.8098 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 28 | 2,564 | $ 2.78 | $ 7,130 | - | 1.38 - 3.50 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 11:46:35 | 1 | $ 2.7984 | USD |
AYTU BioPharma Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 15.31M | 5.57M | - | 107.4M | -17.05M | -3.06 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
AYTU BioPharma News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AYTU Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.68 | 2.94 | 2.68 | 2.83 | 5,711 | 0.07 | 2.61% |
| 1 Month | 3.06 | 3.38 | 2.65 | 3.03 | 16,637 | -0.31 | -10.13% |
| 3 Months | 2.80 | 3.45 | 2.48 | 3.01 | 21,738 | -0.05 | -1.79% |
| 6 Months | 3.20 | 3.45 | 2.20 | 2.79 | 29,198 | -0.45 | -14.06% |
| 1 Year | 2.61 | 3.50 | 1.38 | 2.45 | 74,755 | 0.14 | 5.36% |
| 3 Years | 133.60 | 144.00 | 1.38 | 30.34 | 490,437 | -130.85 | -97.94% |
| 5 Years | 39.80 | 235.286 | 1.38 | 34.79 | 2,192,196 | -37.05 | -93.09% |
AYTU BioPharma Description
| Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. |
